[1]舒 茜,姚峥嵘,王艳翚,等.药品带量采购政策的利益相关者分析[J].卫生经济研究,2019,(08):8-10,12.
　SHU Qian,YAO Zheng-rong,WANG Yan-hui,et al.Stakeholder Analysis of Drug Consumption Policy[J].Journal Press of Health Economics Research,2019,(08):8-10,12.
点击复制

药品带量采购政策的利益相关者分析
分享到：

卫生经济研究[ISSN:1004-7778/CN:33-1056/F]

卷:
期数:
2019年08期
页码:
8-10,12
栏目:
专题研究
出版日期:
2019-07-24

文章信息/Info

Title:
Stakeholder Analysis of Drug Consumption Policy
作者:
舒 茜1 ; 姚峥嵘1 ; 王艳翚1 ; 王丹丹1
1.南京中医药大学卫生经济管理学院，江苏 南京210023
Author(s):
SHU Qian; YAO Zheng-rong; WANG Yan-hui; WANG Dan-dan
School of Health Economics Management，Nanjing University of Chinese Medicine，Nanjing Jiangsu 210023，China
关键词:
药品带量采购; 利益相关者; 药品价格; 医疗机构
Keywords:
quantity purchase of drugs;  stakeholder;  drug price;  medical institution
分类号:
R19
文献标志码:
A
摘要:
“4+7”药品带量采购通过“以量换价”降低药品价格，倒逼医药分家。本文从利益相关者角度出发，分析医药企业、医疗机构和患者在药品带量采购政策中的定位和影响，阐述改革的动力和阻力，为药品带量采购政策的完善和推广提供借鉴。
Abstract:
The “4+7” quantity purchase of drugs has reduced the price of drugs through “quantity-for-price”，which forced the separation of hospitals and medicines. From the perspective of stakeholders，this paper analyzed the positioning and influence of pharmaceutical companies，medical institutions，and patients in the procurement policy of drug consumption，expounded the motivation and resistance of reform，and provided reference for the improvement and promotion of drug procurement policies.

参考文献/References:

[1] 胡善联.中国医改的焦点、难点和痛点[J].卫生经济研究,2015(12):3-7.
[2] 李琛,刘艺敏,王文杰,等.我国药品集中采购工作回顾与展望[J].中国医院管理,2018,38(9):17-19，23.
[3] 傅鸿鹏,陈晓云,张欣,等.药品集中采购的关键问题和对策分析[J].卫生经济研究,2015(9):7-9.
[4] 王忠海,毛宗福,李滔,等.药品集中采购政策改革试点效果评析——以福建省三明市为例[J].中国卫生政策研究,2015 (1):21-26.
[5] 孙晋,闫晓梦.反垄断法视角下药品集团采购(GPO)发展困境及突破——以深圳市GPO被国家发改委叫停事件为切入点[J].甘肃政法学院学报,2018(5):43-55.
[6] 张雪.药品采购“国家第一标”来了 药企或面临不同境遇[J].决策探索(上),2018(12):42-43.
[7] 吕俊,马爱霞,黄文龙.我国医药分业中利益相关者相互关系与对策[J].现代经济探讨,2012(11):59-62.
[8] 李大平.药价虚高的成因分析与治理对策——质疑医药分开[J].卫生经济研究,2011(4):7-9.
[9] 樊长佳,王力男,杨永梅.我国公立医院药品零差率政策实施效果研究[J].卫生经济研究,2019,36(2):53-56.
[10] 赵大仁,何思长,张瑞华,等.我国商业医疗保险的利益相关者分析[J].卫生经济研究,2015(5):37-39.
[11] 胡善联. 购买有价值的医疗卫生服务[J].卫生经济研究,2019(2):3-6.
[12] 金春林，王海银，孙辉，等.价值医疗的概念、实践及其实现路径[J].卫生经济研究,2019(2):6-8.
[13] 杨金国.实行临床路径用药管理 控制医药费用增长[J].中国卫生经济,2010,29(4):91-92.
[14] 金春林,李芬.2017医改畅想[J].中国卫生资源,2017,20(1):1-3.

相似文献/References:

[1]江蒙喜,李卫平.我国公立医院混合所有制改革的利益相关者分析[J].卫生经济研究,2017,(07):18.
[2]卢 慧,魏 来,余昌胤,等.分级诊疗相关利益主体的损益分析[J].卫生经济研究,2018,(02):31.
[3]谭清立,杨思远,李文静,等.“4+7”药品带量采购的效果、关键问题与对策——基于广州的实践[J].卫生经济研究,2020,(04):46.
　TAN Qing-li,YANG Si-yuan,LI Wen-jing,et al.Effects, Key issues and Countermeasures of "4 + 7" Drug Volume-Based Purchasing——Practice Based on Guangzhou[J].Journal Press of Health Economics Research,2020,(08):46.
[4]杜 雪,马 珺,黎雯霞.药品带量采购存在的问题与对策分析[J].卫生经济研究,2020,(08):42.
　DU Xue,MA Jun,LI Wen-xia.Problems and Countermeasures on Existing in the Development of Drug Volume Procurement[J].Journal Press of Health Economics Research,2020,(08):42.
[5]李玉水,康洽福,韩雅清,等.药品带量采购对患者医疗负担的政策效应研究[J].卫生经济研究,2021,38(4):28.
　LI Yu-shui,KANG Qia-fu,HAN Ya-qing,et al.Study on the Policy Effect of Drug Quantity Purchase on Patients' Medical Burden[J].Journal Press of Health Economics Research,2021,38(08):28.
[6]周菁菁,谈在祥.我国药品带量采购政策实施效果研究——以S医院为例[J].卫生经济研究,2021,38(10):52.
　ZHOU Jing-jing,TAN Zai-xiang.Research on the Implementation Effect of Drug Volume Purchasing Policy in China——Taking S Hospital as an Example[J].Journal Press of Health Economics Research,2021,38(08):52.
[7]孙志成,王舒琦,刘 昭,等.利益相关者视角下创新药物筹资支付路径研究[J].卫生经济研究,2022,39(3):9.
　SUN Zhi-cheng,WANG Shu-qi,LIU Zhao,et al.Research on the Pathway of Innovative Drug Financing and Payment from the Perspective of Stakeholders[J].Journal Press of Health Economics Research,2022,39(08):9.
[8]冷楠楠,邱英鹏,赵羽西,等.冠脉支架集中带量采购对医疗服务供给的潜在影响分析[J].卫生经济研究,2022,39(5):1.
　LEN Nan-nan,QIU Ying-peng,ZHAO Yu-xi,et al.Analysis of the Potential Impact of the Policy of Centralized Procurement of Coronary Stents on the Provision of Medical Services[J].Journal Press of Health Economics Research,2022,39(08):1.
[9]罗雪燕,赖 寒,王梦媛,等.省级药品集中带量采购模式对比研究[J].卫生经济研究,2022,39(5):7.
　LUO Xue-yan,LAI Han,WANG Meng-yuan,et al.Comparative Study on the Model of Centralized Volume-Based Procurement of Drugs at the Provincial Level[J].Journal Press of Health Economics Research,2022,39(08):7.
[10]马枋婷,常 峰,路 云,等.我国省级药品带量采购政策比较分析[J].卫生经济研究,2022,39(6):20.
　MA Fangting,CHANG Feng,LU Yun,et al.Comparative Analysis on China's Provincial-Level Drug Volume-Based Procurement Policy[J].Journal Press of Health Economics Research,2022,39(08):20.

更新日期/Last Update: 2019-07-24